Evome Medical Technologies Executes Non-Binding Letter of Intent to Extend Remaining Simbex Acquisition Debt to June 2025; Increases Sales Targets by 7.5% for Biodex Distribution Contracts; Raises Biodex Product Pricing by 2% for 2024
Evome Medical Technologies Executes Non-Binding Letter of Intent to Extend Remaining Simbex Acquisition Debt to June 2025; Increases Sales Targets by 7.5% for Biodex Distribution Contracts; Raises Biodex Product Pricing by 2% for 2024
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company" or "Evome") has executed a non-binding letter of intent (LOI) to extend acquisition debt of US$3,294,440 to the sellers of Simbex, LLC ("Simbex") to June 30, 2025. In exchange for the extensions, the Company intends to grant the Simbex sellers (i) a subordinated security interest in all non-Biodex assets, (ii) a 10% annual interest rate on the amount due from April 14, 2023 to the due date, (iii) cash payments when free cash flow balances of the Company exceed $500,000 after payments to other creditors with priority, and (iv) a waiver from the contractual restriction from holding more than 500,000 common shares of Evome (the "Common Shares") at any one time. As part of the transaction, Simbex sellers have indicated an intention to convert the 4,640,708 Class A non-voting shares (the "Class A Shares") still held into Common Shares.
纽约,2024年2月8日(环球新闻专线)——Evome Medical Technologies Inc.(“公司” 或 “Evome”)签署了一份不具约束力的意向书(LOI),将Simbex, LLC(“Simbex”)卖方的3,294,440美元的收购债务延长至2025年6月30日。作为延期的交换,公司打算授予Simbex卖方(i)所有非Biodex资产的次级担保权益,(ii)从2023年4月14日至到期日到期日的到期金额的10%的年利率,(iii)在向其他优先债权人付款后公司的自由现金流余额超过50万美元时支付现金,以及(iv)免除持有超过50万股普通股的合同限制 Evome(“普通股”)的任意时间。作为交易的一部分,Simbex卖方表示打算将仍持有的4,640,708股A类无表决权股票(“A类股票”)转换为普通股。
The Company has increased sales targets by 7.5% for all distributors in the United States as well as raising Biodex product prices 2% on all products effective January 1, 2024 for the US market. The management believes these new targets and price increases should have a positive impact on the current quarter.
该公司已将美国所有分销商的销售目标提高了7.5%,并将美国市场所有产品的Biodex产品价格提高了2%,自2024年1月1日起生效。管理层认为,这些新目标和价格上涨将对本季度产生积极影响。
"I am pleased we were able to restructure and extend this last part of our acquisition debt obligation," said Mike Seckler, CEO of Evome Medical Technologies Inc. "This enables the Company to use capital in the coming quarters to accelerate growth and work towards building cash on our balance sheet. 2024 is shaping up to be an exciting year for us. We have two new products we expect to launch shortly. We have a new sales and marketing team that has improved our distribution contracts by incorporating performance metrics including volume minimums. We have reorganized the board of directors and the top management to focus on our business plan. This debt extension follows my plan to provide time and space to execute our business plan over the next 18 months. As part of the negotiations with the Simbex sellers, we made sure this debt extension did not violate any of the terms of our previous agreement executed with holders of our other acquisition debt and our current bank lines."
Evome Medical Technologies Inc.首席执行官迈克·塞克勒说:“我很高兴我们能够重组和延长收购债务的最后一部分。这使公司能够在未来几个季度使用资本来加速增长并努力在资产负债表上积累现金。2024年对我们来说将是激动人心的一年。我们预计不久将推出两款新产品。我们有一个新的销售和营销团队,通过纳入包括最低销量在内的绩效指标,改善了我们的分销合同。我们重组了董事会和高层管理人员,将重点放在业务计划上。此次债务延期遵循我的计划,即在未来18个月内为执行我们的业务计划提供时间和空间。作为与Simbex卖方谈判的一部分,我们确保此次债务延期没有违反我们先前与我们的其他收购债务和当前银行额度持有人签订的协议的任何条款。”
For more information please contact:
欲了解更多信息,请联系:
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: info@evomemedical.com
迈克·塞克勒
首席执行官
电话:1 (800) 760-6826
电子邮件:info@evomemedical.com
Additional Information
附加信息
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险交易所及其监管服务提供商(该术语在the 多伦多证券交易所风险投资交易所的policies 中定义)均不对本release 的充分性或准确性承担责任。
Unless otherwise specified, all dollar amounts in this press release are expressed in Canadian dollars.
除非另有说明,否则本新闻稿中的所有美元金额均以加拿大元dollars 表示。
Certain statements contained in this press release constitute "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as "expects" "believes", "estimates", "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", and "anticipate", and similar expressions as they relate to the Company, including: the Company executing a definitive agreement with the Simbex sellers and closing the transaction as contemplated by the LOI disclosed herein; and the timing and number of products the Company intends to launch. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: the successfully negation and execution of a definitive agreement related to the LOI disclosed herein; the Company receiving all necessary approvals for the transaction described herein; and all conditions to closing the transaction described herein being satisfied or waived. The Company cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
本新闻稿中包含的某些陈述构成meaning ofthe《私人证券诉讼改革法》和适用的加拿大证券laws 中的 “前瞻性信息”。这些陈述可以be 通过使用诸如 “期望” “相信”、“估计”、“可能”、“会”、 “可以” 等前瞻性术语来识别, “应该”、“潜在”、 “会”、“寻找”、“打算”、 “计划” 和 “预测”,以及与relateto 公司类似的表述,包括:公司与公司签订最终协议Simbex按照此处披露的意向书的设想卖出并完成交易;以及公司打算推出产品的时间和数量。除historical 事实陈述外,所有statementsother 都可能是前瞻性的 信息。这样statementsreflect 公司目前对未来events 的看法和意图,以及current 信息availableto 公司,并面临某些风险,uncertainties 和assumptions,包括:成功否定和执行与本文披露的意向书有关的最终协议;公司获得所有必要的批准for 本文所述的交易;以及所有conditions 以完成本文所述的交易感到满意或被放弃。该公司警告说,包含herein 的the 前瞻性陈述受重要factors 的限定,这可能会导致actual 业绩与such 陈述所反映的结果存在重大差异。这些因素include 但是are 不限于general 业务和economicconditionsregions inwhich the Companyoperates;公司执行密钥的能力priorities,includingsuccessful 完成ofacquisitions、业务 留存和 战略计划和吸引、发展and 留住关键executives;困难integrating 新收购的企业;ongoing 或者供应出现新的中断chain,extent 和such 供应链中断的范围,以及解决问题的时机或程度or 改善such 中断;ability 到 实施业务战略并根据公司信息开展业务opportunities;disruptions in 或attacks(包括cyber-attacks)technology、互联网、网络接入或其他voiceor datacommunications 系统或服务;各类欺诈或其他行为的evolutioncriminal 对whichthe 公司的行为是风险的;failure 需要遵守其义务 公司或其affiliates; 对现行法律法规的变更或适用的影响;newgranting of 许可证and 许可证in 一家监管严格的企业;overall 很难litigation 环境,包括美国States;竞争加剧;外币汇率变化;increasedfundingcosts 还有市场volatility 到期to 市场流动性不足和资金竞争;availability 资金andresources 用于开展业务;criticalaccounting 会计准则的估计和变更、policies、 和公司使用的方法;theoccurrence 既自然又不自然 灾难性eventsand 声称resulting 来自此类事件;以及thoserisk 讨论的因素或referred 到intheCompany 的披露documents 向美国Securities 和Exchange 委员会提交andavailable 位于www .sec.gov,还有the 证券监管机构in 肯定有provinces 的Canada 和available 在。在unexpectedmanner 中,是否有任何factor 会影响公司,还是assumptions 标的the 前瞻性information 证明不正确,实际的results 或events 可能与or 事件预测的结果materially 有所不同。Any 如此具有前瞻性informationisexpressly 根据这份警示符在其entirety 中获得资格statement。此外,the Companydoes 不要假设responsibility 的准确性或completenessforwardinformation。The 前瞻性information 包含在本新闻稿中is 截至本报的daterelease 而且公司承诺no 有义务公开更新或修改any forward-lookinginformation,other 超出了适用的law 的要求。